<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Encainide and flecainide increase cardiac mortality</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Encainide and flecainide increase cardiac mortality</h1>
<div class="graphic"><div class="figure"><div class="ttl">Encainide and flecainide increase cardiac mortality</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Results of the Cardiac Arrhythmia Suppression Trial (CAST) in patients with ventricular premature beats after myocardial infarction. Patients receiving encainide or flecainide had, when comparedÂ with those receiving placebo, a significantly lower rate of avoiding a cardiac event (death or resuscitated cardiac arrest) (left panel, p = 0.001) and a lower overall survival (right panel, p = 0.0006). The cause of death was arrhythmia or cardiac arrest.</div><div class="graphic_reference">Data from Echt DS, Liebson PR, Mitchell B, et al. N Engl J Med 1991; 324:781.</div><div id="graphicVersion">Graphic 59975 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
